TRINETRA › Sectors › Healthcare
Panacea Biotec Limited (PANACEABIO) — share price, P/E and fundamentals
Panacea Biotec Limited (NSE: PANACEABIO) closed at ₹311.10 on 30 Oct 2026, -30.3% over one year, against a 52-week range of ₹292.40 – ₹647.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 13 Aug 2026) it reported revenue of ₹200 cr and net profit of ₹2 cr, a 1.2% net margin; revenue grew 19.7% and profit fell 45.6% year on year.
No trailing P/E is published: trailing twelve-month earnings are negative (-7 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.
From the balance sheet dated 31 Mar 2026: return on equity 1.1%, ROCE 2.1%, debt-to-equity 0.03, Piotroski F-score 5 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 5% of 64 sector peers; PBT margin higher than 3% of 64 sector peers; ROE higher than 6% of 64 sector peers.
Key figures
| Last close | ₹311.10 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -17.0% / -15.6% / -30.3% |
| 52-week low – high | ₹292.40 – ₹647.00 |
| Market capitalisation | ₹1,907 cr |
| Price / book | 2.28 |
| EV / EBITDA | 65.6 |
| TTM EPS | ₹-1.16 |
| TTM net profit | ₹-7 cr |
| Quarter revenue | ₹200 cr |
| Quarter net profit | ₹2 cr |
| Net margin | 1.2% |
| Revenue growth (YoY) | +19.7% |
| Profit growth (YoY) | -45.6% |
| Return on equity | 1.1% |
| ROCE | 2.1% |
| Debt / equity | 0.03 |
| Current ratio | 1.47 |
| Free cash flow | ₹-37 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹2.7 cr |
Against Healthcare peers
| Metric | PANACEABIO | Peer median | Percentile |
|---|---|---|---|
| Net margin | 1.15 | 12.89 | 5 |
| PBT margin | 1.79 | 17.68 | 3 |
| ROE | 1.10 | 13.87 | 6 |
| ROCE | 2.08 | 17.26 | 5 |
| Debt / equity | 0.03 | 0.11 | 37 |
| P/B | 2.28 | 6.02 | 7 |
| EV/EBITDA | 65.55 | 22.34 | 100 |
Questions
What were Panacea Biotec Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Panacea Biotec Limited reported revenue of ₹200 cr and net profit of ₹2 cr (consolidated), filed with the exchange on 13 Aug 2026.
What is Panacea Biotec Limited's ROE?
Return on equity is 1.1% based on the balance sheet dated 31 Mar 2026.
Does Panacea Biotec Limited have debt?
Debt-to-equity is 0.03 on the balance sheet dated 31 Mar 2026.
What is PANACEABIO's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, PANACEABIO traded between ₹292.40 and ₹647.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.